Systemic lupus erythematosus: clinical features in patients with a disease duration of over 10 years, first evaluation

被引:78
作者
Swaak, AJG
van den Brink, HG
Smeenk, RJT
Manger, K
Kalden, JR
Tosi, S
Marchesoni, A
Domljan, Z
Rozman, B
Logar, D
Pokorny, G
Kovacs, L
Kovacs, A
Vlachoyiannopoulos, PG
Moutsopoulos, HM
Chwalinska-Sadowska, H
Dratwianka, B
Kiss, E
Cikes, N
Branimir, A
Schneider, M
Fischer, R
Bombardieri, S
Mosca, M
Graninger, W
Smolen, JS
机构
[1] Cent Lab, Bloodtransfus Serv, Dept Autoimmune Dis, Amsterdam, Netherlands
[2] Univ Erlangen Nurnberg, Dept Internal Med 3, D-8520 Erlangen, Germany
[3] Univ Erlangen Nurnberg, Inst Clin Immunol, D-8520 Erlangen, Germany
[4] Ist Ortoped Gaetano Pini, Rheumatol Unit, Milan, Italy
[5] Univ Zagreb, Dept Rheumatol & Rehabil, Zagreb 41000, Croatia
[6] Dr Peter Drzaj Hosp, Dept Rheumatol, Ljubljana, Slovenia
[7] Dr A Szent Gyorgyi Med Univ Ctr, Dept Internal Med 1, Szeged, Hungary
[8] Dr A Szent Gyorgyi Med Univ Ctr, Blood Transfus Inst, Szeged, Hungary
[9] Natl Univ Athens, Sch Med, Dept Pathophysiol, Athens, Greece
[10] Inst Rheumatol, Dept Connect Tissue Dis, Warsaw, Poland
[11] Debrecen Univ Med, Dept Internal Med, H-4012 Debrecen, Hungary
[12] Univ Hosp Ctr, Dept Med, Div Clin Immunol & Rheumatol, Zagreb, Croatia
[13] Univ Dusseldorf, Dept Rheumatol, Med Clin, D-4000 Dusseldorf, Germany
[14] Univ Pisa, Dipartimento Med Interna, Pisa, Italy
[15] Univ Vienna, Dept Rheumatol, Vienna, Austria
关键词
SLE; disease activity; SLEDAI; ECLAM; Damage Index;
D O I
10.1093/rheumatology/38.10.953
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Most information available about the disease course of patients with systemic lupus erythematosus (SLE) is restricted to the first 5 yr after disease onset. Data about the disease course 10 yr after disease onset are rare. The aim of this multicentre study was to describe the outcome of SLE patients with a disease duration of >10 yr. Methods. Outcome parameters were the SLE Disease Activity Index (SLEDAI); the European Consensus Lupus Activity Measure (ECLAM), the Systemic Lupus International Collaborative Clinics/American College of Rheumatology Damage Index (SLICC/ACR), a global damage index (DI) and required treatment. In 10 different European rheumatology centres, all SLE patients who were evaluated in the last 3 months of 1994, and who had been diagnosed with SLE at least 10 yr ago, were included in the study. Results. It should be stressed that our results are confined to a patient cohort, defined by a disease duration of at least 10 yr, and who are still under clinical care at the different centres in Europe. These SLE patients still showed some disease activity, related to symptoms of the skin and musculoskeletal systems, next to the presence of renal involvement. A total of 72% of the patients needed treatment with prednisolone (less than or equal to 7.5 mg). The cumulative damage was overall related to clinical features of the central nervous system (14%) and renal involvement (14%), next to deforming arthritis (14%), osteoporosis (15%) and hypertension (40%). The prevalences of obesity, Cushing appearance and diabetes are highly suggestive that the ongoing treatment and that in the past might have had an impact on the total sum of endorgan damage. Conclusions. After 10 yr, a high proportion of patients in our cohort continued to show evidence of active disease, defined by the SLEDAI as well as ECLAM. The DI was related to the involvement of the central nervous system, renal involvement and the presence of hypertension.
引用
收藏
页码:953 / 958
页数:6
相关论文
共 19 条
[1]   DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS [J].
BOMBARDIER, C ;
GLADMAN, DD ;
UROWITZ, MB ;
CARON, D ;
CHANG, CH .
ARTHRITIS AND RHEUMATISM, 1992, 35 (06) :630-640
[2]   SYSTEMIC LUPUS-ERYTHEMATOSUS - CLINICAL AND IMMUNOLOGICAL PATTERNS OF DISEASE EXPRESSION IN A COHORT OF 1,000 PATIENTS [J].
CERVERA, R ;
KHAMASHTA, MA ;
FONT, J ;
SEBASTIANI, GD ;
GIL, A ;
LAVILLA, P ;
DOMENECH, I ;
AYDINTUG, AO ;
JEDRYKAGORAL, A ;
DERAMON, E ;
GALEAZZI, M ;
HAGA, HJ ;
MATHIEU, A ;
HOUSSIAU, F ;
INGELMO, M ;
HUGHES, GRV ;
CERVERA, R ;
SEBASTIANI, GD ;
FONT, J ;
KHAMASHTA, MA ;
HUGHES, GRV ;
FONT, J ;
CERVERA, R ;
LOPEZSOTO, A ;
VIVANCOS, J ;
INGELMO, M ;
URBANOMARQUEZ, A ;
KHAMASHTA, MA ;
VIANNA, J ;
HUGHES, GRV ;
GIL, A ;
LAVILLA, P ;
PINTADO, V ;
LOPEZDUPLA, M ;
VAZQUEZ, JJ ;
SEBASTIANI, GD ;
DERAMON, E ;
CAMPS, M ;
FRUTOS, MA ;
PERELLO, I ;
SANTOS, PG ;
ABARCA, M ;
NEBRO, AF ;
DOMENECH, I ;
TOKGOZ, G ;
AYDINTUG, AO ;
JEDRYKAGORAL, A ;
MALDYKOWA, H ;
CHWALINSKASADOWSKA, H ;
GALEAZZI, M .
MEDICINE, 1993, 72 (02) :113-124
[3]   Remission of systemic lupus erythematosus [J].
Drenkard, C ;
Villa, AR ;
GarciaPadilla, C ;
Esther, R ;
PerezVazquez, ME ;
AlarconSegovia, D .
MEDICINE, 1996, 75 (02) :88-98
[6]  
DUBOIS EL, 1964, JAMA-J AM MED ASSOC, V190, P140
[7]   NATURAL HISTORY OF SYSTEMIC LUPUS ERYTHEMATOSUS BY PROSPECTIVE ANALYSIS [J].
ESTES, D ;
CHRISTIAN, CL .
MEDICINE, 1971, 50 (02) :85-+
[8]   The development and initial validation of the systemic lupus international collaborating clinics American College of Rheumatology Damage Index for Systemic Lupus Erythematosus [J].
Gladman, D ;
Ginzler, E ;
Goldsmith, C ;
Fortin, P ;
Liang, M ;
Urowitz, M ;
Bacon, P ;
Bombardieri, S ;
Hanly, J ;
Hay, E ;
Isenberg, D ;
Jones, J ;
Kalunian, K ;
Maddison, P ;
Nived, O ;
Petri, M ;
Richter, M ;
SanchezGuerrero, J ;
Snaith, M ;
Sturfelt, G ;
Symmons, D ;
Zoma, A .
ARTHRITIS AND RHEUMATISM, 1996, 39 (03) :363-369
[9]  
Gladman DD, 1996, CLIN EXP RHEUMATOL, V14, P305
[10]  
GLADMAN DD, 1987, J RHEUMATOL, V14, P223